Animated Banner

Logo and text fade out and scroll out of top of frame as footnote copy scrolls in from the bottom, and these next two frames will start to scroll at the 27th second. They will continue to scroll past the 30th second point till the material has run through. And there will be a bar at the right for a user to go back on the blue content on these two frames.

First frame text fades out; new copy slides in from bottom of frame and fixes into place next to graphic.

Graphic and type scroll out of the top of the frame as the logo and message slide in from the bottom and fix into place.

Preceding Information

Instructions for Use

Full Scrolling ISI

(continued)

Nuclear Imaging

Increased hematopoietic activity of the bone marrow in response to growth factor therapy has been associated with transient positive bone imaging changes. This should be considered when interpreting bone imaging results.

Most common adverse reactions

• Rash
• Pain in extremity

Please see Neulasta® full Precribing Information.

Special instructions for the on-body injector (OBI) for Neulasta®

A healthcare provider must fill the on-body injector (OBI) with Neulasta® using the co-packaged prefilled syringe and then apply the OBI to the patient's skin (abdomen or back of arm). The back of the arm may only be used if there is a caregiver available to monitor the status of the OBI. Approximately 27 hours after the OBI is applied to the patient's skin, Neulasta® will be delivered over approximately 40 minutes. A healthcare provider may initiate administration with the OBI on the same day of dosing, whenever the OBI demonstrates adequate delivery. As the OBI delivers Neulasta® no less than 24 hours after the administration of pegfilgrastim chemotherapy.

The prefilled syringe-co-packaged in the Neulasta® Onpro® kit contains additional solution to compensate for fluid loss during delivery through the OBI. If this syringe is used for manual subcutaneous injection, the patient will receive an overdose. If the prefilled syringe for manual use is used with the OBI, the patient may receive less than the recommended dose.

Do not use the OBI to deliver any other drug product except the Neulasta® prefilled syringe-co-packaged with the OBI. Use of the OBI has not been studied in pediatric patients.

The OBI should be applied to intact, non-intimated skin on the arm or abdomen.

A missed dose could occur due to an OBI failure or leakage. Instead patients using the OBI to notify their healthcare professional immediately in order to determine the need for a replacement dose of pegfilgrastim if they suspect that the device may not have performed as intended. If the patient misses a dose, a new dose should be administered by single prefilled syringe for manual use as soon as possible after detection.

Review the Patient Information and Patient Instructions for Use with the patient and provide the instructions to the patient. Refer to the Healthcare Provider Instructions for Use for the OBI for full administration information.

For any OBI problems, call Amgen at 1-800-772-6436 or 1-844-4MY-NEULASTA (1-844-696-3952).

References:


© 2020 Amgen Inc. All rights reserved. Not for reproduction. USA-00368073 09-20
160x600

**Information and Important Safety Information:**

Neutraspan® (bevacizumab) is indicated for the treatment of patients with metastatic colorectal cancer to improve survival. Neutraspan® should be administered under the supervision of a qualified physician.

**Drug Class:**

Antineoplastic agent

**Contraindications:**

- Patients with allergy to bevacizumab.
- Pregnancy and breastfeeding.
- Patients with active gastrointestinal perforation or bleeding.

**Warnings/Precautions:**

- Renal and hepatic impairment.
-AUTHOR OF THE DOCUMENT.

**Full Scrolling UI:**

- First frame text fades out; graphic scrolls up slightly as new copy slides in from bottom of frame and fixes into place.

- Graphic and type scroll out of the top of the frame as the logo and message slide in from bottom of frame and fixes into place.

- Previous frame text fades out and new text fades in below.

- Previous frame text fades out and new text fades in below.

- Logo and text fade out and scroll out of the top of frame as footnote copy scrolls in from bottom of frame; continue scrolling till the material has run through. They will continue to scroll past the 30th second point as the next two frames will start scrolling at the 27th second.

- The user can go back on the blue content on these two frames.

**Graphic and type:**

- A logo and message slide in from bottom of frame and fixes into place.

- Previous frame text fades out and new text fades in below.

- Previous frame text fades out and new text fades in below.

- Previous frame text fades out and new text fades in below.

- Logo and text fade out and scroll out of the top of frame as footnote copy scrolls in from bottom of frame; continue scrolling till the material has run through. They will continue to scroll past the 30th second point as the next two frames will start scrolling at the 27th second.

- The user can go back on the blue content on these two frames.
Graphic and type scroll up from bottom of frame and fixes in place.

First frame text scrolls out top of frame, new copy slides in from bottom of frame and fixes into place next to graphic.

Graphic and type scroll out of the top of the frame as the logo and message slide in from the bottom and fix into place.

Previous frame text scrolls out of the top of the frame and new text scrolls in from bottom and fixes in place next to logo.

Previous frame text scrolls out of the top of the frame and new text scrolls in from bottom and fixes in place next to logo.

Logo and text scroll out of top of frame as footnote copy scrolls in from the bottom, and these next four frames will start to scroll/slide left to right at the 27th second. They will continue to scroll past the 30th second point till the material has run through. And there will be a bar at the right for a user to go back on the blue content on these four frames.

Full Scrolling ISI

Graphic and type scroll up from bottom of frame and fixes in place.

First frame text scrolls out top of frame, new copy slides in from bottom of frame and fixes into place next to graphic.

Graphic and type scroll out of the top of the frame as the logo and message slide in from the bottom and fix into place.

Previous frame text scrolls out of the top of the frame and new text scrolls in from bottom and fixes in place next to logo.

Full Scrolling ISI

Nuclear Imaging

- Increased hematopoietic activity of the bone marrow in response to growth factor therapy has been associated with transient positive bone imaging findings. This should be considered when interpreting bone imaging results.

Most common adverse reactions

- Bone pain
- Pain in extremity

Please see Neulasta® full Prescribing Information

Special instructions for the on-body injector (OBI) for Neulasta®

A healthcare provider must fill the on-body injector (OBI) with Neulasta® using the on-body injector prefilled syringe and then apply the OBI to the patient's skin. Neulasta® will be delivered over approximately 65 minutes. A healthcare provider may initiate administration with the OBI on the same day as the administration of cyclosporine chemotherapy, as long as the OBI delivers Neulasta® no less than 24 hours after the administration of cyclosporine chemotherapy. The prefilled syringe co-packaged in the Neulasta® OBI kit contains additional solution to compensate for liquid loss during delivery through the OBI. If the syringe is used for manual subcutaneous injection, the patient will receive an overdose. If the prefilled syringe for manual use is used with the OBI, the patient may receive less than the recommended dose. Do not use the OBI to deliver any other drug product except the Neulasta® prefilled syringe co-packaged with the OBI. The use of the OBI has not been studied in pediatric patients.

The OBI should be applied to intact, non-initiated skin on the arm or abdomen.

A missed dose could occur due to an OBI failure or leakage. Instruct patients using the OBI to notify their healthcare professional immediately in order to determine the need for a replacement dose of pegfilgrastim if they suspect that the device may have been damaged. If the OBI does not dispense a dose, a new dose should be administered by single prefilled syringe for manual use as soon as possible after detection.

Review the Patient Information and Patient Instructions for Use with the patient to provide Instructions to the patient.

Refer to the Neulasta® OBI product labeling and/or provider instructions for Use for the OBI for full administration information.

For OBI, call 1-800-722-6435 or 1-844-MYNEUHALA (1-844-696-3452)